Rituximab treatment of idiopathic membranous nephropathy

Slides:

Advertisements

Similar presentations

Kamyar Kalantar-Zadeh Kidney International

Advertisements

Volume 69, Issue 11, Pages (June 2006)

Improved patient/technique survival and peritonitis rates in patients treated with automated peritoneal dialysis when compared to continuous ambulatory.

Volume 81, Issue 2, Pages (January 2012)

Volume 69, Issue 11, Pages (June 2006)

Beta blockers in the management of chronic kidney disease

Membranous nephropathy: When and how to treat

Mycophenolate mofetil treatment for primary glomerular diseases

Seasonal variations and age-related changes in human sperm count, motility, motion parameters, morphology, and white blood cell concentration Grace M.

Graph (box plots) shows primary tumor volumes of oral and maxillary sinus (A) and pharyngeal (B) cancers categorized at T1–T4. Graph (box plots) shows.

C-reactive protein and dialysis access

Volume 71, Issue 10, Pages (May 2007)

Volume 71, Issue 8, Pages (April 2007)

Kamyar Kalantar-Zadeh Kidney International

Volume 70, Pages S21-S25 (December 2006)

Volume 73, Issue 11, Pages (June 2008)

The progression of chronic kidney disease: A 10-year population-based study of the effects of gender and age B.O. Eriksen, O.C. Ingebretsen Kidney International

A new era in phosphate binder therapy: What are the options?

Volume 70, Issue 11, Pages (December 2006)

Volume 61, Issue 6, Pages (June 2002)

Volume 73, Issue 7, Pages (April 2008)

D. Coyne Kidney International Volume 69, Pages S1-S3 (May 2006)

Volume 69, Issue 2, Pages (January 2006)

Enlightenment on liver lanthanum exposure

Bradley A. Ford, Daniel W. Coyne, Charles S. Eby, Mitchell G. Scott

Volume 71, Issue 4, Pages (February 2007)

Volume 73, Pages S5-S17 (April 2008)

Dedicated outpatient vascular access center decreases hospitalization and missed outpatient dialysis treatments R. Mishler, J.J. Sands, N.J. Ofsthun,

Prospective randomized study of individual and group psychotherapy versus controls in recipients of renal transplants1 Lyndsay S. Baines, John T. Joseph,

Volume 65, Issue 2, Pages (February 2004)

Improved patient/technique survival and peritonitis rates in patients treated with automated peritoneal dialysis when compared to continuous ambulatory.

Volume 69, Issue 9, Pages (May 2006)

Blood pressure targets in hemodialysis patients

Volume 70, Issue 8, Pages (October 2006)

Fructose intake as a risk factor for kidney stone disease

The third World Kidney Day: Looking back and thinking forward

Volume 72, Issue 12, Pages (December 2007)

Volume 80, Issue 12, Pages (December 2011)

Volume 66, Issue 2, Pages (August 2004)

Volume 69, Issue 12, Pages (June 2006)

Volume 69, Issue 3, Pages (February 2006)

Volume 64, Issue 1, Pages (July 2003)

Volume 73, Issue 5, Pages (March 2008)

Environmental exposure to lead and progressive diabetic nephropathy in patients with type II diabetes J.-L. Lin, D.-T. Lin-Tan, C.-C. Yu, Y.-J. Li, Y.-Y.

Volume 69, Issue 8, Pages (April 2006)

Volume 71, Issue 7, Pages (April 2007)

Volume 71, Issue 4, Pages (February 2007)

Higher serum C-reactive protein predicts short and long-term outcomes in peritoneal dialysis-associated peritonitis N.-Y. Zalunardo, C.-L. Rose, I.W.Y.

Volume 71, Issue 12, Pages (June 2007)

Serum cystatin C-immunoglobulin high-molecular-weight complexes in kidney and liver transplant patients Jesús Hermida, Rafael Romero, J. Carlos Tutor

The valuable contribution of observational studies to nephrology

Organ transplantation goes to the movies

Volume 72, Issue 3, Pages (August 2007)

Is it the low-protein diet or simply the salt restriction?

Treatment of the primary hyperoxalurias: A new chapter

Volume 74, Issue 7, Pages (October 2008)

Volume 70, Issue 3, Pages (August 2006)

Urinalysis in Western culture: A brief history

Volume 70, Issue 3, Pages (August 2006)

Volume 69, Issue 11, Pages (June 2006)

Assessing the impact of different imputation methods on serial measures of renal function: The Strong Heart Study N.-M. Shara, J.-G. Umans, W. Wang,

ANCA comes of age—but with caveats

Volume 71, Issue 9, Pages (May 2007)

Advisory about gadolinium calls for caution in the treatment of uremic patients with lanthanum carbonate S. Aime, C. Canavese, P. Stratta Kidney International

Volume 70, Issue 5, Pages (September 2006)

T cells and T-cell receptors in acute renal failure

The International Pediatric Peritonitis Registry: Starting to walk

Volume 80, Issue 9, Pages (November 2011)

Prediction in idiopathic membranous nephropathy

E.F. Vonesh, J.J. Snyder, R.N. Foley, A.J. Collins

Presentation transcript:

Rituximab treatment of idiopathic membranous nephropathy F.C. Fervenza, F.G. Cosio, S.B. Erickson, U. Specks, A.M. Herzenberg, J.J. Dillon, N. Leung, I.M. Cohen, D.N. Wochos, E. Bergstralh, M. Hladunewich, D.C. Cattran Kidney International Volume 73, Issue 1, Pages 117-125 (January 2008) DOI: 10.1038/sj.ki.5002628 Copyright © 2008 International Society of Nephrology Terms and Conditions

Figure 1 Box plots of urine protein by months since start of rituximab therapy. The top and bottom of the box are the estimated 75th and 25th percentiles, respectively. The intermediate horizontal line and ‘+’ sign represent the median and mean urine protein, respectively. The vertical lines extend to the largest (smallest) data point, that is, within 1.5 times the interquartile range (75th–25th percentile) above the 75th percentile (or below the 25th). The number of patients with follow-up at 0, 1, 3, 6, 9, and 12 months are 15, 15, 15, 14, 14, and 14, respectively. Kidney International 2008 73, 117-125DOI: (10.1038/sj.ki.5002628) Copyright © 2008 International Society of Nephrology Terms and Conditions

Figure 2 Changes in serum IgG, IgA, and IgM levels following treatment with rituximab. *P<0.05. Kidney International 2008 73, 117-125DOI: (10.1038/sj.ki.5002628) Copyright © 2008 International Society of Nephrology Terms and Conditions

Figure 3 Dynamics of CD19+ B cells in patients with IMN versus RA versus ANCA-associated vasculitis. Patients with IMN and RA were treated with rituximab 1 g i.v. on days 1 and 15. Patients with ANCA-associated vasculitis received rituximab 375 mg m−2 i.v. on days 1, 8, 15, and 22. Kidney International 2008 73, 117-125DOI: (10.1038/sj.ki.5002628) Copyright © 2008 International Society of Nephrology Terms and Conditions